TIM
GBT

Tevis Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Tevis Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-120
Closed -$4K – 527
2022
Q1 		$4K Hold
120
– – ﹤0.01% 456
2021
Q4 		$4K Buy
+120
New +$3.72K ﹤0.01% 507

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Tevis Investment Management's GBT Position: Q2 2022 in Review

Tevis Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 120 shares — an estimated $4K sold.

Tevis Investment Management first reported a position in GBT in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Tevis Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Tevis Investment Management sold 120 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $4K.
  • Tevis Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 2 quarters.
  • Tevis Investment Management's Global Blood Therapeutics, Inc. position peaked at $4K in Q1 2022.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Tevis Investment Management's 13F filing for Q2 2022, filed 8 Aug 2022.